NCT03524612 - A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

November 2, 2018

Primary Completion Date

October 22, 2021

Study Completion Date

October 3, 2022

Conditions

Immune Thrombocytopenic Purpura (ITP)

Interventions

DRUG

eltrombopag

12.5, 25, 50 and 75 mg tablets for oral use once daily

Trial Locations (32)

123

Novartis Investigative Site, Muscat

3010

Novartis Investigative Site, Bern

4010

Novartis Investigative Site, Linz

10960

Hematology Oncology Association of Rockland, Nyack

14000

Novartis Investigative Site, Mexico City

14033

Novartis Investigative Site, Caen

22030

Novartis Investigative Site, Edirne

28009

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

28222

Novartis Investigative Site, Madrid

29010

Novartis Investigative Site, Málaga

30008

Novartis Investigative Site, Murcia

33604

Novartis Investigative Site, Pessac

34129

Novartis Investigative Site, Trieste

37007

Novartis Investigative Site, Salamanca

40138

Novartis Investigative Site, Bologna

41380

Novartis Investigative Site, Kocaeli

44160

Novartis Investigative Site, Guadalajara

125167

Novartis Investigative Site, Moscow

191024

Novartis Investigative Site, Saint Petersburg

2540364

Novartis Investigative Site, Viña del Mar

4800827

Novartis Investigative Site, Temuco

44106-5000

Case Western Reserve, Cleveland

41253-190

Novartis Investigative Site, Salvador

20211-030

Novartis Investigative Site, Rio de Janeiro

05319-000

Novartis Investigative Site, São Paulo

115 27

Novartis Investigative Site, Athens

265 00

Novartis Investigative Site, Pátrai

466-8650

Novartis Investigative Site, Nagoya

08035

Novartis Investigative Site, Barcelona

09100

Novartis Investigative Site, Aydin

W12 0HS

Novartis Investigative Site, London